Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.50 |
| ▸ | GABRE | P78334 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1555914 | 1.00 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL1555911 | 0.98 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL517314 | 0.86 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31301833 | 0.85 | ANPEP (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28302938 | 0.85 | HDAC3 (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16449783 | 0.85 | GABRP (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL7262836 | 0.85 | GABRP (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16449780 | 0.85 | GABRP (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL321317 | 0.83 | HDAC3 (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6000874 | 0.83 | CA1 (0.44) | CYP2D6HDAC6HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170319717-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, Inc. | 2017-11-09 | — | — | US | disclosed |
| US-8883792-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2013-10-17 | — | — | US | disclosed |
| CN-101215288-A | Novel beta-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-09 | — | — | CN | disclosed |
| CN-100379738-C | Novel beta-lactam compound and process for producing the same | SUMITOMO PHARMA (JP) | 2008-04-09 | — | — | CN | disclosed |
| EP-1340756-B1 | NOVEL BETA-LACTAM COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7163936-B2 | β-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163936-B2 | β-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20040102433-A1 | Novel beta-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| CN-1484645-A | Novel beta-lactam compound and process for producing the same | ס����ҩ��ʽ���� | 2004-03-24 | — | — | CN | disclosed |
| EP-1340756-A1 | NOVEL BETA-LACTAM COMPOUNDS AND PROECSS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102433-A1 | Novel beta-lactam compounds and process for producing the same | MRPL21, MCRS1, RPS4X | GABRP 2259/4885GABRD 1680/4885GABRA1 2033/4885 |
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT2A1, SULT1A1, SFPQ | GABRP 3181/4885GABRD 3316/4885GABRA1 2310/4885 |
| US-20170319717-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | KLK3, FOLH1, CD47 | GABRP 1012/4885GABRD 2781/4885GABRA1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.